Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267072
Status:
COMPLETED
Last Update Posted:
2018-01-09
First Post:
2005-12-19
Brief Title:
Ovarian Screening Study
Sponsor:
University of Louisville
Organization:
University of Louisville
Study Overview
Official Title:
The University of Louisville Ovarian Screening Study
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are
To identify women at increased risk for developing ovarian cancer
To detect ovarian cancers at an early stage
To investigate the role of tumor membrane fragments as tumor markers for early ovarian carcinoma
To identify women at increased risk for developing ovarian cancer
To detect ovarian cancers at an early stage
To investigate the role of tumor membrane fragments as tumor markers for early ovarian carcinoma
Detailed Description:
In the year 2001 approximately 23400 women in the USA are expected to be diagnosed with ovarian carcinoma and 13900 will die of the disease This means that within the USA more women die annually from ovarian cancer than all other gynecologic malignancies combined Within the Commonwealth of Kentucky approximately 250 women per year develop ovarian carcinoma
Survival for patients with ovarian cancer is directly related to the stage of disease at diagnosis Unfortunately the majority of women present with advanced disease Stage III and IV and most of these patients will die of the disease
The aim of screening for ovarian cancer is to reduce the morbidity and mortality by detecting the disease at an early stage since ovarian cancer detected when disease is confined to the ovary Stage I is associated with a dramatically improved 5-year survival Disease confined to the ovary may be cured in over 90 of patients in some cases without the need for chemotherapy
Survival for patients with ovarian cancer is directly related to the stage of disease at diagnosis Unfortunately the majority of women present with advanced disease Stage III and IV and most of these patients will die of the disease
The aim of screening for ovarian cancer is to reduce the morbidity and mortality by detecting the disease at an early stage since ovarian cancer detected when disease is confined to the ovary Stage I is associated with a dramatically improved 5-year survival Disease confined to the ovary may be cured in over 90 of patients in some cases without the need for chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None